PAM
PYXS icon

Panagora Asset Management’s Pyxis Oncology PYXS Stock Holding History

Panagora Asset Management’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-69,424
Closed -$101K – 1271
2026
Q1 		$101K Buy
+69,424
New +$105K ﹤0.01% 1136

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Panagora Asset Management's PYXS Position: Q2 2026 in Review

Panagora Asset Management sold out of Pyxis Oncology (PYXS) in Q2 2026, closing a stake of 69,424 shares — an estimated $101K sold.

Panagora Asset Management first reported a position in PYXS in Q1 2026 and held it in 1 quarter. The position peaked at $101K in Q1 2026. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Panagora Asset Management reported no remaining Pyxis Oncology position as of Q2 2026 after selling out during the quarter.
  • Panagora Asset Management sold 69,424 Pyxis Oncology shares in Q2 2026, an estimated $101K.
  • Panagora Asset Management first reported a position in Pyxis Oncology in Q1 2026 and held it in 1 quarter.
  • Panagora Asset Management's Pyxis Oncology position peaked at $101K in Q1 2026.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.